Cáncer de mama en el norte del Perú

This study aimed to understand the immunohistochemical profile of breast cancer and to identify the HER2 low subgroup in the northern macro-region of Peru. A cross-sectional study was conducted in 1176 patients from the Regional Institute of Neoplastic Diseases Northern Peru, from January 2016 to December 2023. We analyzed the data (age, histological type, grade and complementary results), with frequencies and percentages. The profile corresponded to: luminal B (45.6%); luminal A (24.7%); triple negative (18.2%); and HER2 positive non luminal (11.5%). In addition, 215 patients presented HER2 low (25.1% of those previously considered negative). This study provides evidence that the subtyping of breast cancer has changed, being luminal B the most frequent. It is essential to involve health policies to acquire targeted therapies considering HER2 low patients. Motivation for the study. Molecular classification of breast cancer allows the use of targeted treatments. Information on this profile in the northern macroregion of Peru is unknown. In addition, new therapies have appeared for a subgroup of patients. Main findings. In this study, the most frequent molecular subtypes were: luminal B, luminal A, triple negative and non-luminal HER2. Also, 18.3% of patients had low HER2 expression. Implications. Health policies should be aligned with scientific advances, to guarantee targeted therapies and to update the information in health manuals or protocols

Breast cancer · Cancer · Geography · Gynecology · Cervical Cancer and HPV Research · HER2/EGFR in Cancer Research · Medicine · Monoclonal and Polyclonal Antibodies Research · Internal Medicine · Oncology

• Características clínicas y pronosticas de los subtipos moleculares de cáncer de mama determinados por Inmunohistoquímica. Arequipa, Perú

  Open Access•Gonzalo Arturo Medina Bueno•Revista Peruana de Medicina…•2017

  Add to list